Mouse Anti-Human Elafin protein monoclonal antibody, clone 2G5

Electroencephalography (EEG) is one of the most signals used for studying and demonstrating the electrical activity of the brain due to the absence of side effects, its noninvasive nature and its well temporal resolution. Indeed, it provides real-time information, so it can be easily suitable for predicting drivers' vigilance states. The classification of these states through this signal requires sophisticated approaches in order to achieve the best prediction performance. Furthermore, deep learning (DL) approaches have shown a good performance in learning the high-level features of the EEG signal and in resolving classification issues. In this paper, we will predict individuals' states of vigilance based on the study of their brain activity by analyzing EEG signals using DL architectures. In fact, we propose two types of networks: (i) a 1D-UNet model, which is composed only of deep one-dimensional convolutional neural network (1D-CNN) layers and (ii) 1D-UNet-long short-term memory (1D-UNet-LSTM) that combines the proposed 1D-UNet architecture with the LSTM recurrent model. The experimental results reveal that the suggested models can stabilize the training model, well recognize the subject vigilance states and compete with the state of art on multiple performance metrics. The per-class average of precision and recall can be, respectively, up to 86% with 1D-UNet and 85% with 1D-UNet-LSTM, hence the effectiveness of the proposed methods. In order to complete our virtual prototyping and to get a real evaluation of our alert equipment, these proposed DL models are implemented also on a Raspberry Pi3 device allowing measuring the execution time necessary for predicting the state vigilance in real time.

Serum and plasma contain abundant biological information that reflect the body's physiological and pathological conditions and are therefore a valuable sample type for disease biomarkers. However, comprehensive profiling of the serological proteome is challenging due to the wide range of protein concentrations in serum. Methods: To address this challenge, we developed a novel in-depth serum proteomics platform capable of analyzing the serum proteome across similar to 10 orders or magnitude by combining data obtained from Data Independent Acquisition Mass Spectrometry (DIA-MS) and customizable antibody microarrays. Results: Using psoriasis as a proof-of-concept disease model, we screened 50 serum proteomes from healthy controls and psoriasis patients before and after treatment with traditional Chinese medicine (YinXieLing) on our in-depth serum proteomics platform. We identified 106 differentially-expressed proteins in psoriasis patients involved in psoriasis-relevant biological processes, such as blood coagulation, inflammation, apoptosis and angiogenesis signaling pathways. In addition, unbiased clustering and principle component analysis revealed 58 proteins discriminating healthy volunteers from psoriasis patients and 12 proteins distinguishing responders from non-responders to YinXieLing. To further demonstrate the clinical utility of our platform, we performed correlation analyses between serum proteomes and psoriasis activity and found a positive association between the psoriasis area and severity index (PASI) score with three serum proteins (PI3, CCL22, IL-12B). Conclusion: Taken together, these results demonstrate the clinical utility of our in-depth serum proteomics platform to identify specific diagnostic and predictive biomarkers of psoriasis and other immune-mediated diseases.